$11.69
0[0.00%]
At close: Apr 25
$11.69
0[0.00%]
PreMarket: 4:20PM EDT
Stoke Therapeutics
(NASDAQ:STOK)Stoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, Predictions
Stoke Therapeutics Inc has a consensus price target of $20.73, established from looking at the 41 latest analyst ratings. The last 3 analyst ratings were released from Needham, Cantor Fitzgerald, and Wedbush on April 11, 2024, April 4, 2024, and March 26, 2024. With an average price target of $13 between Needham, Cantor Fitzgerald, and Wedbush, there's an implied 11.21% upside for Stoke Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Cantor Fitzgerald
Wedbush
Canaccord Genuity
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Stoke Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 88.2% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 03/26/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 45.42% | Wedbush | Laura Chico | $13 → $17 | Maintains | Outperform | Get Alert |
| 03/26/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 79.64% | Canaccord Genuity | Sumant Kulkarni | $18 → $21 | Maintains | Buy | Get Alert |
| 03/26/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 11.21% | JP Morgan | Jessica Fye | $6 → $13 | Maintains | Neutral | Get Alert |
| 03/26/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | — | TD Cowen | Yaron Werber | — | Upgrade | Hold → Buy | Get Alert |
| 03/26/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 199.4% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 88.2% | Needham | Joseph Stringer | $14 → $22 | Maintains | Buy | Get Alert |
| 02/16/2024 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 19.76% | Needham | Joseph Stringer | → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 19.76% | Needham | Joseph Stringer | $25 → $14 | Maintains | Buy | Get Alert |
| 08/08/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 19.76% | Cantor Fitzgerald | Charles Duncan | $18 → $14 | Maintains | Overweight | Get Alert |
| 08/08/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 96.75% | Credit Suisse | Judah Frommer | → $23 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 199.4% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 113.86% | Needham | Joseph Stringer | → $25 | Reiterates | → Buy | Get Alert |
| 07/31/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 199.4% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 113.86% | Needham | Joseph Stringer | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 199.4% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 113.86% | Cantor Fitzgerald | Charles Duncan | $20 → $25 | Maintains | Overweight | Get Alert |
| 05/05/2023 | STOK | Buy Now | Stoke Therapeutics | $11.69 | 139.52% | Credit Suisse | Judah Frommer | → $28 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for Stoke Therapeutics (STOK)?
The latest price target for Stoke Therapeutics (NASDAQ: STOK) was reported by Needham on April 11, 2024. The analyst firm set a price target for $22.00 expecting STOK to rise to within 12 months (a possible 88.20% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Stoke Therapeutics (STOK)?
The latest analyst rating for Stoke Therapeutics (NASDAQ: STOK) was provided by Needham, and Stoke Therapeutics reiterated their buy rating.
When was the last upgrade for Stoke Therapeutics (STOK)?
The last upgrade for Stoke Therapeutics Inc happened on March 26, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Stoke Therapeutics Inc.
When was the last downgrade for Stoke Therapeutics (STOK)?
There is no last downgrade for Stoke Therapeutics.
When is the next analyst rating going to be posted or updated for Stoke Therapeutics (STOK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stoke Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stoke Therapeutics was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Stoke Therapeutics (STOK) correct?
While ratings are subjective and will change, the latest Stoke Therapeutics (STOK) rating was a reiterated with a price target of $0.00 to $22.00. The current price Stoke Therapeutics (STOK) is trading at is $11.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.